Dieses Ergebnis aus Springer Nature Journals kann Gästen nicht angezeigt werden. Login für vollen Zugriff.

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

Title:	Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks
Authors:	Alexis, Andrew F.^{Aff1, IDs40257025009842_cor1}; Bukhalo, Michael^Aff2; Cook-Bolden, Fran E.^Aff3; Del Rosso, James Q.^Aff4; Draelos, Zoe D.^Aff5; DuBois, Janet C.^Aff6; Ferris, Laura K.^Aff7; Forman, Seth B.^Aff8; Kempers, Steven E.^Aff9; Kircik, Leon H.^{Aff10, Aff11, Aff12}; Lain, Edward^Aff13; Moore, Angela Y.^{Aff14, Aff15}; Pariser, David M.^Aff16; Raoof, Joseph^Aff17; Zirwas, Matthew J.^Aff18; Seal, Melissa S.^Aff19; Kato, Saori^Aff19; Chu, David H.^Aff19; Krupa, David^Aff19; Snyder, Scott^Aff19; Burnett, Patrick^Aff19; Berk, David R.^Aff19
Source:	American Journal of Clinical Dermatology. 27(1):189-198
Database:	Springer Nature Journals